3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
19
Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer
2
Small Cell Lung Carcinoma
1
Recurrence
1
Prostate Adenocarcinoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Follicular
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bulbo-Spinal Atrophy, X-Linked
1
Bites and Stings
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
Letrozole
25
Fulvestrant
25
Specimen Handling
19
ribociclib
16
Capecitabine
16
pembrolizumab
14
palbociclib
14
Paclitaxel
14
Trastuzumab
13
Carboplatin
13
exemestane
12
abemaciclib
12
Tamoxifen
12
Anastrozole
12
Magnetic Resonance Spectroscopy
11
trastuzumab deruxtecan
8
pertuzumab
8
Biopsy
8
Goserelin
7
inavolisib
6
giredestrant
6
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
patritumab deruxtecan
5
eribulin
5
elacestrant
5
Taxes
5
Standard of Care
5
Radiotherapy
5
Gonadotropin-Releasing Hormone
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
enzalutamide
×
30 days
×
Clear all
No trials found.